iRhythm Technologies
IRTC
104.99
-2.21
-2.06%
iRhythm Technologies
US · IRTC
#2372 by market cap
Listed 2016
104.99
-2.21
-2.06%
Live - 5344 symbols - heartbeat 377s ago
· 2026-10-08 05:22
Pre-market
103.50
-1.42%
After-hours
104.00
-0.94%
- Market cap
- 3.46B
- P/E (TTM)i
- -249.98
- P/Bi
- 18.61
- EPSi
- -1.39
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on IRTC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.50, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +26.24% YoY
Margins
- Gross margin
- 70.57%
- Operating margin
- -7.09%
- Net margin
- -5.96%
Key ratios & quality
- Enterprise valuei
- 3.54B
- Altman Z-Scorei
- 2.50
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147.28M | 214.55M | 265.17M | 322.83M | 410.92M | 492.68M | 591.84M | 747.14M |
| Gross profit | 108.48M | 162.07M | 194.89M | 213.57M | 281.63M | 331.81M | 407.53M | 527.25M |
| Selling & admin expenses | 133.31M | 179.52M | 197.23M | 274.84M | 322.20M | 385.65M | 418.57M | 492.55M |
| Research & development | 20.86M | 37.30M | 41.33M | 38.67M | 46.61M | 60.24M | 103.83M | 87.65M |
| Operating profit | -45.69M | -54.76M | -43.67M | -99.94M | -87.18M | -114.08M | -114.86M | -52.95M |
| Pretax profit | -50.33M | -54.50M | -43.60M | -100.99M | -115.89M | -122.66M | -112.72M | -43.60M |
| Tax | 44.00K | 65.00K | 229.00K | 367.00K | 269.00K | 750.00K | 565.00K | 953.00K |
| Net profit | -50.38M | -54.57M | -43.83M | -101.36M | -116.16M | -123.41M | -113.29M | -44.55M |
| Basic EPS | -2 | -2 | -2 | -3 | -4 | -4 | -4 | -1 |
| Diluted EPS | -2.11 | -2.16 | -1.58 | -3.46 | -3.88 | -4.04 | -3.63 | -1.39 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 158.68M | 186.69M | 192.88M | 208.89M | 199.39M | 224.17M |
| Gross profit | 109.22M | 132.86M | 137.12M | 148.06M | 141.35M | 163.21M |
| Selling & admin expenses | 119.96M | 126.38M | 124.22M | 122.00M | 135.88M | 131.66M |
| Research & development | 21.82M | 22.71M | 21.34M | 21.79M | 21.65M | 20.14M |
| Operating profit | -32.56M | -16.23M | -8.43M | 4.27M | -16.19M | 11.41M |
| Pretax profit | -30.04M | -14.40M | -5.19M | 6.03M | -13.43M | -381.00K |
| Tax | 665.00K | -183.00K | 24.00K | 447.00K | 500.00K | 0 |
| Net profit | -30.70M | -14.22M | -5.21M | 5.58M | -13.93M | -381.00K |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.97 | -0.44 | -0.16 | 0.17 | -0.43 | -0.01 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 104.30M | 172.79M | 377.83M | 305.52M | 288.77M | 230.81M | 645.82M | 702.77M |
| Cash & ST investments | 78.34M | 140.55M | 335.22M | 239.13M | 213.14M | 133.76M | 535.55M | 583.76M |
| Inventory | 2.06M | 4.04M | 5.31M | 10.27M | 15.16M | 13.97M | 14.04M | 21.63M |
| Total assets | 117.52M | 306.21M | 511.74M | 462.97M | 448.22M | 433.14M | 931.45M | 1.02B |
| Total current liabilities | 30.33M | 52.07M | 65.67M | 87.85M | 89.10M | 107.37M | 110.92M | 151.89M |
| Short-term debt | -- | 9.86M | 19.84M | 22.81M | 13.03M | 15.16M | 15.87M | 16.69M |
| Long-term debt | 34.90M | 32.99M | 21.34M | 9.69M | 34.94M | 34.95M | 646.44M | 649.50M |
| Total liabilities | 65,386,000.00 | 170,803,000.00 | 170,127,000.00 | 183,452,000.00 | 208,410,000.00 | 223,047,000.00 | 840,541,000.00 | 867,296,000.00 |
| Total equity | 52.14M | 135.41M | 341.61M | 279.52M | 239.81M | 210.10M | 90.91M | 152.75M |
| Retained earnings | -205.83M | -260.39M | -304.68M | -406.05M | -522.20M | -645.61M | -758.90M | -803.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 636.01M | 663.92M | 680.04M | 702.77M | 680.56M | 755.95M |
| Cash & ST investments | 520.59M | 545.54M | 565.21M | 583.76M | 549.62M | 591.27M |
| Inventory | 14.34M | 18.40M | 19.56M | 21.63M | 23.80M | 22.51M |
| Total assets | 926.10M | 964.03M | 995.21M | 1.02B | 1.01B | 1.09B |
| Total current liabilities | 111.34M | 132.21M | 146.91M | 151.89M | 131.75M | 196.10M |
| Short-term debt | 16.14M | 16.36M | 16.53M | 16.69M | 16.79M | 61.91M |
| Long-term debt | 647.24M | 648.01M | 648.75M | 649.50M | 650.31M | 651.10M |
| Total liabilities | 839,433,000.00 | 860,370,000.00 | 873,321,000.00 | 867,296,000.00 | 845,155,000.00 | 907,443,000.00 |
| Total equity | 86.67M | 103.66M | 121.89M | 152.75M | 161.21M | 185.98M |
| Retained earnings | -789.60M | -803.81M | -809.03M | -803.45M | -817.38M | -817.76M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -29.09M | -21.86M | -13.76M | -37.75M | -23.01M | -50.10M | 3.39M | 80.86M |
| Depreciation & amortization | 2.27M | 3.45M | 12.93M | 16.59M | 19.61M | 22.14M | 25.78M | 26.48M |
| Free cash flow | -34.27M | -42.32M | -27.31M | -65.82M | -52.84M | -90.53M | -45.55M | 34.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 107.37M | 206.03M | -- | 0 | 0 | -25.00M | 0 |
| Ending cash balance | 20.02M | 20.46M | 88.63M | 127.56M | 78.83M | 36.17M | 427.96M | 244.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -7.89M | 27.66M | 34.88M | 26.21M | -26.17M | 51.08M |
| Depreciation & amortization | 6.60M | 6.53M | 6.62M | 6.73M | 6.55M | 6.75M |
| Free cash flow | -17.31M | 17.29M | 20.05M | 14.49M | -33.08M | 37.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 383.64M | 317.46M | 263.96M | 244.37M | 248.50M | 255.04M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -72.07 | -57.49 | -18.38 | -32.64 | -44.73 | -54.86 | -75.27 | -36.57 |
| ROA %i | -38.19 | -25.62 | -10.72 | -20.80 | -25.50 | -28.00 | -16.60 | -4.57 |
| ROIC %i | -45.69 | -29.39 | -11.74 | -23.34 | -29.45 | -35.25 | -20.56 | -5.93 |
| 5-year avg ROE %i | -- | -- | -- | -44.05 | -46.09 | -41.76 | -45.18 | -48.81 |
| EBIT margin %i | -30.63 | -24.64 | -15.87 | -30.92 | -27.19 | -24.15 | -16.88 | -4.07 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 4.62 |
| Current ratioi | 3.44 | 3.32 | 5.75 | 3.48 | 3.24 | 2.15 | 5.82 | 4.63 |
| Quick ratioi | 3.24 | 3.16 | 5.56 | 3.25 | 2.95 | 1.82 | 5.55 | 4.34 |
| Debt / assetsi | 29.70 | 42.00 | 23.93 | 25.43 | 29.24 | 29.97 | 79.11 | 71.68 |
| LT debt / equityi | 66.94 | 87.69 | 30.04 | 33.95 | 49.21 | 54.58 | 793.16 | 467.77 |
| Interest coveragei | -14.49 | -32.17 | -27.70 | -85.39 | -27.01 | -32.60 | -7.79 | -2.31 |
| Revenue CAGR (3Y) %i | 59.73 | 49.61 | 38.82 | 29.90 | 24.19 | 22.94 | 22.39 | 22.05 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -111.13 | -91.13 | -53.15 | -36.57 | -22.42 | -9.63 |
| ROA %i | -10.71 | -9.82 | -5.40 | -4.57 | -2.88 | -1.36 |
| ROIC %i | -12.95 | -12.00 | -6.85 | -5.93 | -3.83 | -2.07 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -13.69 | -12.17 | -5.15 | -4.07 | -1.76 | 0.02 |
| FCF / sales %i | -- | 1.96 | 4.61 | 4.62 | 2.38 | 4.72 |
| Current ratioi | 5.71 | 5.02 | 4.63 | 4.63 | 5.17 | 3.85 |
| Quick ratioi | 5.40 | 4.75 | 4.37 | 4.34 | 4.79 | 3.44 |
| Debt / assetsi | 79.42 | 76.22 | 73.65 | 71.68 | 72.47 | 70.64 |
| LT debt / equityi | 830.05 | 693.02 | 587.80 | 467.77 | 441.97 | 381.99 |
| Interest coveragei | -6.81 | -6.87 | -2.48 | -2.31 | -1.05 | 0.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Contracted third-party payors is the largest reported line at 50.76% of revenue, across 4 reported segments.
- Centers for Medicare & Medicaid Services follows at 26.12%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Contracted third-party payors50.76%
Centers for Medicare & Medicaid Services26.12%
Healthcare Institutions16.85%
Non-contracted third-party payors6.27%
Quote time 2026-10-08 05:22:02 · For reference only, not investment advice and not tailored to your situation.